BioSpace News Archive

Data from the oral presentation at the 59th American Society of Hematology Annual Meeting (ASH) held in Atlanta, Georgia demonstrate that ALX148 triggers a broad antitumor response by bridging innate and adaptive immunity.

BioMarin announced today an update to its previously reported results of an open-label Phase I/II study of valoctocogene roxaparvovec.

Seattle Genetics, Inc. today highlighted updated results from the phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) in CD30-expressing cutaneous T-cell lymphoma (CTCL) at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Atlanta, Georgia, December 9-12, 2017.

Magenta Therapeutics announced the presentation of preclinical data from its CD117 antibody-drug conjugate (ADC) conditioning program.

Early evidence suggests that gene therapy developed at St. Jude Children’s Research Hospital will lead to broad protection for infants with the devastating immune disorder X-linked severe combined immunodeficiency disorder.

Tetra Bio-Pharma announced today that the Company has accepted the suggestion of Health Canada to change the order of its clinical trial application (CTA) review process.

The extended follow-up data demonstrated that patients treated with IMBRUVICA earlier (after first relapse) experienced the best clinical outcomes, in terms of both efficacy and tolerability.

The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta and demonstrate the safety profile and efficacy of CALQUENCE in the management of previously-treated mantle cell lymphoma (MCL).

Abatacept, when added to the standard drug regimen used to prevent GvHD, reduced the occurrence of acute, grade III-IV GvHD from 32 to 3 percent in pediatric and adult patients who underwent mismatched unrelated donor stem cell transplants to treat advanced cancer and other blood disorders.

Results showed Alpine’s ICOSL vIgD-Fc fusion proteins demonstrated therapeutic efficacy, including suppressing an allogeneic immune response in vitro, improving survival, and reducing GvHD disease activity.